baha the information company

baha is a leading provider of real-time market data, financial news, technology and solutions for the financial industry. baha offers real-time data terminals for professionals, global financial market data covering over 12 million financial instruments on more than 150 exchanges, as well as 24/7 breaking news with global coverage and free web and mobile apps. From a total of around 200 real-time data providers worldwide, only Reuters 1851, Bloomberg 1981 and now baha in 2021 were named after the founder.

Inventiva SA/ FR0013233012 /

6/5/2024 5:35:07 PM	Chg. -0.040	Volume	Bid5:35:07 PM	Ask5:35:07 PM	High	Low
3.280EUR	-1.20%	8,277 Turnover: 27,104.220	3.250Bid Size: 44	3.280Ask Size: 249	3.315	3.250

GlobeNewswire 5/30 Combined General Meeting of June 20, 2024 - Availability of the preparatory documents

GlobeNewswire 5/22 Inventiva announces two scientific presentations at the EASL International Liver Congress™ 2024

GlobeNewswire 5/21 Inventiva reports 2024 First Quarter Financial Information¹ and provides a corporate update

GlobeNewswire 5/16 Inventiva announces the positive recommendation of the fourth DMC of the NATiV3 Phase III clinical t...

GlobeNewswire 5/13 Inventiva announces the publication in Nature Communications of additional results from NATIVE Phase...

GlobeNewswire 4/3 Inventiva announces filing of its 2023 Universal Registration Document and 2023 Annual Report on For...

GlobeNewswire 3/28 Inventiva announces the nomination of Andre Turenne as Director

GlobeNewswire 3/27 Inventiva reports its 2023 full-year results

GlobeNewswire 3/22 Inventiva announces the schedule of publication and presentation of its 2023 Full-Year Financial Res...

GlobeNewswire 3/18 Inventiva announces positive results from the Phase II, LEGEND, Proof-of-Concept study combining lan...

GlobeNewswire 3/18 PRISM MarketView Spotlights Companies Leading the Charge in Liver Disease Treatment Following Landma...

GlobeNewswire 3/13 Inventiva to present the results of LEGEND Phase IIa combination trial with lanifibranor and empagli...

GlobeNewswire 3/7 Inventiva announces that screening in the NATiV3, Phase III, clinical trial evaluating lanifibranor ...

GlobeNewswire 2/15 Inventiva reports preliminary 2023 fiscal year financial Information¹ and provides an update on its ...

GlobeNewswire 1/24 Half-Year Review of Inventiva’s Liquidity Contract with Kepler Cheuvreux

GlobeNewswire 1/10 Inventiva draws down the second tranche of €25 million under existing Finance Contract with the Euro...

GlobeNewswire 12/4/2023 Inventiva announces the positive recommendation of the third DMC of the Phase III clinical trial wit...

GlobeNewswire 11/21/2023 Inventiva reports 2023 Third Quarter Financial Information¹

GlobeNewswire 11/6/2023 Inventiva announces a late breaker abstract and two additional abstracts on its lead compound, lanif...

GlobeNewswire 10/9/2023 ROTH MKM to Host Healthcare Opportunities Conference on October 12th at the Yale Club in New York Ci...

GlobeNewswire 9/28/2023 Inventiva reports its 2023 first-half financial results and provides a corporate update

GlobeNewswire 9/20/2023 Inventiva and Hepalys Pharma, Inc. announce exclusive licensing agreement to develop and commercial...

GlobeNewswire 8/31/2023 Inventiva announces a financing of approximately €35.7 million from new and existing investors, cons...

GlobeNewswire 3/8/2022 Inventiva announces that its IND application for the Phase II combination trial with lanifibranor a...

GlobeNewswire 3/7/2022 Inventiva reports its 2021 Full-Year Results: key milestones achieved with lanifibranor in NASH and ...

Inventiva SA/ FR0013233012 /

If you wish to receive reply to your feedback, please provide your email address.